In brief
The Trump administration has announced a major cut in Medicare prices for 15 popular prescription drugs, marking a significant win for American seniors and taxpayers. Health Secretary Robert F. Kennedy Jr. emphasized the government's commitment to making healthcare more affordable, following the implementation of a law allowing Medicare to negotiate drug prices. Many of the new deals involve treatments for conditions like diabetes and asthma, with expected savings reaching billions.
NEW YORK (AP) — Pharmaceutical companies have agreed to slash Medicare prices for 15 prescription drugs after months of negotiations. These reductions are expected to produce billions in savings for taxpayers and older adults.
The new prices, while significantly lower, may vary for Medicare recipients at their pharmacy counters depending on individual plans and spending. Health Secretary Robert F. Kennedy Jr. hailed this effort as part of the administration’s move to address affordability issues among Americans.
This announcement completes a second round of negotiations under a 2022 law that enables Medicare to negotiate prices on its most widely used and expensive prescription drugs, boosting the total negotiated drugs to 25. The new prices will take effect in 2027, following the initial 10 drugs negotiated last year, set to go into effect in January.
Drugs Affected Include Popular Treatments
The recently negotiated prices target popular prescriptions, including weight-loss and diabetes medications like Ozempic, Rybelsus, and Wegovy. Other drugs involved include Trelegy Ellipta for asthma and others that treat a range of conditions from arthritis to various cancers.
Dr. Mehmet Oz, administrator of the Centers for Medicare and Medicaid Services, highlighted that the administration's efforts have yielded substantially better outcomes for Americans compared to previous negotiations, with the potential to save Medicare about $8.5 billion yearly if these deals had been in place last year.
Medicare will also continue to negotiate prices for more drugs next year, following the establishment of a new rule that caps out-of-pocket costs for beneficiaries at $2,000.
Despite the positive outlook on these health initiatives, some pharmaceutical companies are contesting these negotiations, claiming they threaten future innovations in the medical field.
Next year marks another round of negotiations for 15 additional drugs, signaling ongoing efforts to make healthcare more accessible for Americans!
